Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15545264 | 0.85 | KDM4E (0.41) | KDM4EALDH1A1HPGDKLK7CA2 | |
| SCHEMBL2351369 | 0.85 | CA2 (0.54) | KDM4EALDH1A1HPGDKLK7CA2 | |
| SCHEMBL14015776 | 0.72 | KDM4E (0.43) | KDM4EALDH1A1HPGDKLK7 | |
| SCHEMBL9429738 | 0.64 | CA2 (0.43) | CA2 | |
| SCHEMBL9429518 | 0.64 | CA2 (0.43) | CA2 | |
| SCHEMBL25796608 | 0.61 | CA2 (0.37) | CA2 | |
| SCHEMBL10077371 | 0.60 | KDM4E (0.54) | KDM4EALDH1A1HPGDKLK7 | |
| SCHEMBL22714603 | 0.60 | KDM4E (0.63) | KDM4EALDH1A1HPGDKLK7 | |
| SCHEMBL9819024 | 0.59 | KDM4E (0.61) | KDM4EALDH1A1HPGDKLK7 | |
| SCHEMBL10569736 | 0.58 | CA2 (0.44) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263787-B2 | Process for preparing dorzolamide | CIPLA LIMITED (IN) | 2012-09-11 | — | — | US | disclosed |
| WO-2010061398-A1 | PROCESS FOR PREPARING DORZOLAMIDE HYDROCHLORIDE AND ITS INTERMEDIATE | SUVEN LIFE SCIENCES LIMITED (IN) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113804-A1 | Process for Preparing Dorzolamide | CIPLA LIMITED (IN) | 2010-05-06 | — | — | US | disclosed |
| EP-0296879-B1 | SUBSTITUTED AROMATIC SULFONAMIDES AS ANTIGLAUCOMA AGENTS | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
| US-4863922-A | Substituted aromatic sulfonamides as antiglaucoma agents, compositions and use | MERCK & CO., INC. (US) | 1989-09-05 | — | — | US | disclosed |
| EP-0296879-A1 | Substituted aromatic sulfonamides as antiglaucoma agents | MERCK & CO. INC. (US) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113804-A1 | Process for Preparing Dorzolamide | SQOR, PPOX, DAO | KDM4E 2357/4885ALDH1A1 275/4885HPGD 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.